Portal de Periódicos da CAPES

Carta Produção Nacional Revisado por pares

BIBTEX RIS

Letter to the Editor: Issues on COVID-19 Pathogenesis

2020; Mary Ann Liebert, Inc.; Volume: 34; Issue: 5 Linguagem: Inglês

10.1089/vim.2020.0059

1557-8976

José Valter Joaquim Silva Júnior, Thaísa Regina Rocha Lopes, Pablo Sebastian Britto de Oliveira, Rudi Weiblen, Eduardo Furtado Flores,

COVID-19 Clinical Research Studies

Viral ImmunologyVol. 34, No. 5 Letters to the EditorFree AccessLetter to the Editor: Issues on COVID-19 PathogenesisJosé Valter Joaquim Silva Júnior, Thaísa Regina Rocha Lopes, Pablo Sebastian Britto de Oliveira, Rudi Weiblen, and Eduardo Furtado FloresJosé Valter Joaquim Silva JúniorAddress correspondence to: Dr. José Valter Joaquim Silva Júnior, Virology Sector, Department of Preventive Veterinary Medicine, Federal University of Santa Maria, Av. Roraima, 1000, Camobi, Santa Maria, Rio Grande do Sul 97105-900, Brazil E-mail Address: [email protected]Virology Sector, Laboratory of Immunopathology Keizo Asami, Federal University of Pernambuco, Pernambuco, Brazil.Department of Microbiology and Parasitology, Federal University of Santa Maria, Santa Maria, Brazil.Virology Sector, Department of Preventive Veterinary Medicine, Federal University of Santa Maria, Santa Maria, Brazil.Search for more papers by this author, Thaísa Regina Rocha LopesVirology Sector, Laboratory of Immunopathology Keizo Asami, Federal University of Pernambuco, Pernambuco, Brazil.Search for more papers by this author, Pablo Sebastian Britto de OliveiraVirology Sector, Department of Preventive Veterinary Medicine, Federal University of Santa Maria, Santa Maria, Brazil.Search for more papers by this author, Rudi WeiblenVirology Sector, Department of Preventive Veterinary Medicine, Federal University of Santa Maria, Santa Maria, Brazil.Search for more papers by this author, and Eduardo Furtado FloresAddress correspondence to: Dr. Eduardo Furtado Flores, Virology Sector, Department of Preventive Veterinary Medicine, Federal University of Santa Maria, Av. Roraima, 1000, Camobi, Santa Maria, Rio Grande do Sul 97105-900, Brazil E-mail Address: [email protected]Virology Sector, Department of Preventive Veterinary Medicine, Federal University of Santa Maria, Santa Maria, Brazil.Search for more papers by this authorPublished Online:14 Jun 2021https://doi.org/10.1089/vim.2020.0059AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookXLinked InRedditEmail To the Editor:Coronaviruses belong to the realm Riboviria, order Nidovirales and family Coronaviridae, which have two subfamilies, Letovirinae and Orthocoronavirinae. The subfamily Orthocoronavirinae comprises four genera, Alphacoronavirus, Betacoronavirus, Gammacoronavirus and Deltacoronavirus (15). Among these, only the alpha- and betacoronaviruses are known to infect humans. To date, seven human coronaviruses have been identified: HCoV-229E, HCoV-NL63, HCoV-OC43, HCoV-HKU1, SARS-CoV (Severe acute respiratory syndrome-related coronavirus), MERS-CoV (Middle East respiratory syndrome-related coronavirus) and SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2) (6). HCoV-229E, HCoV-NL63 (both alphacoronaviruses), HCoV-OC43 and HCoV-HKU1 (both betacoronaviruses) are often related to mild diseases, but may also lead to clinical complications in specific populations, for example, young, elderly and immunocompromised individuals. Infections with SARS-CoV, MERS-CoV and SARS-CoV-2 (betacoronaviruses), in turn, are strongly associated with severe respiratory diseases (6,19,32).Human coronavirus infections have been reported since the 1960s, initially by HCoV-229E (8,19). However, only in 2002 and later, in 2012, coronaviruses attracted worldwide attention with the emergence of SARS-CoV and MERS-CoV, respectively (3,29). SARS-CoV circulated between November 2002 and July 2003, infecting 8,098 individuals and leading to 774 deaths (3,4). MERS-CoV emerged in 2012 and has so far caused 2,494 infections and 858 deaths (29). More recently, in November/December 2019, a new coronavirus, named SARS-CoV-2, emerged in Hubei province, mainland China, and has been responsible for the "new coronavirus disease" (coronavirus disease 2019, COVID-19) (12,32). At the moment, COVID-19 has assumed a pandemic status (30).On February 14, 2020, an article by "The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team" opened a horizon for discussions on SARS-CoV-2 and COVID-19 (21). In mainland China, as of February 11, 2020, the highest death rates by COVID-19 occurred in individuals >60 years old and no death was recorded in children <9 years old. In addition, hypertension, diabetes and cardiovascular disease would be risk factors for COVID-19 (21). This epidemiological profile raises several issues that must be discussed, for example: (i) why the highest rates of both critical COVID-19 and death in the elderly?; (ii) why the opposite situation for children?; and (iii) why would hypertension, diabetes and cardiovascular disease be associated with more severe COVID-19?Antibody-dependent enhancement (ADE) resulting from successive infections by antigenically related viruses has been extensively described and recognized as an important mechanism of viral pathogenesis. In vitro and/or in vivo evidence of ADE has been reported for several viruses, such as human immunodeficiency (11), influenza (28), Ebola (18) and dengue (DENV) viruses (10).Regarding coronaviruses, several studies have also reported in vitro and/or in vivo ADE for SARS-CoV (16,17,27), MERS-CoV (26) and animal coronaviruses, for example, Feline infectious peritonitis virus (FIPV) (7,14,24). In this regard, an issue is imperative: would it be possible for antibodies induced by previous infections with other human coronaviruses to lead to SARS-CoV-2 ADE? If this possibility is real, ADE may be an additional factor to explain the greater severity of COVID-19 in the elderly, since they probably had more opportunities to be infected by coronaviruses throughout their lives.Although previous authors have considered some of these aspects (2,23), an issue has not yet been addressed: could maternal antibodies against other human coronaviruses influence the course of SARS-CoV-2 infection in newborn and/or young children? In dengue—an interesting model for ADE studies—maternal anti-DENV antibodies transmitted to fetuses can protect newborns from DENV infections. However, as neutralizing antibody levels decline after the 4th or 6th month of life, ADE outweighs virus neutralization and the infant has an increased risk to develop severe forms of dengue (5). Regarding COVID-19, would it be possible that maternal antibodies for other human coronaviruses, ADE-related (?), and against SARS-CoV-2 (potentially virus neutralizing) have a similar dynamics?In addition to these issues, it is very important to highlight that in natural infections by human coronaviruses, the participation of cells expressing receptors for the antibody fragment crystallizable (Fc) region is still unclear. Consequently, a possible role of ADE in SARS-CoV-2 infections should be cautiously taken.Recent studies have also identified the angiotensin converting enzyme 2 (ACE2) as the cell receptor used by SARS-CoV-2; the same receptor identified for SARS-CoV (13,25). Therefore, the hypothesis that cell conditions that increase ACE2 expression would facilitate SARS-CoV-2 infection may be plausible. Cunningly, Fang et al. (9) suggested that "patients with cardiac diseases, hypertension, or diabetes, who are treated with ACE2-increasing drugs, are at higher risk for severe COVID-19." Indeed, this observation probably helps to explain the high risk of severe COVID-19 in individuals with these morbidities.Amid the whirlwind of SARS-CoV-2 information, a piece of news released by the media drew attention: individuals previously tested positive for COVID-19 returned to be viral RNA-positive after a period of negative diagnosis. Although these samples need also to be investigated for the presence of infectious viral particles, this finding raised the question of whether these individuals had been reinfected or whether they had intermittent viral shedding.The possibility that these individuals have been cured and then early reinfected does not seem plausible, at least from the immunological point of view. Previous studies with human and animal coronaviruses report the development of an adaptive immune response postinfection or postimmunization (1,24,31). It is also important to note that the possibility of an early reinfection would reduce the hope of a pandemic decline through massive vaccination.Regarding intermittent viral shedding, herein it is opportune to make a parallel with animal coronaviruses. Infectious bronchitis virus (IBV), for example, is a highly contagious gammacoronavirus that targets the upper respiratory tract of chickens for primary replication, but then reaches other tissues, leading to a multisystemic infection. Interestingly, IBV has long being recognized as a virus that causes prolonged or intermittent shedding. In these cases, some sites have been proposed for virus persistence, such as kidneys, caecal tonsils and respiratory tract (20,22).In COVID-19, it should not be disregarded that SARS-CoV-2 could use a similar mechanism of persistence in specific cells/tissues. As the systemic SARS-CoV-2 infection is still uncertain, we suggest starting the investigation of a possible viral persistence in respiratory tract cells. In addition to deepening the knowledge about the virus–host interaction, this information would have important implications on the SARS-CoV-2 containment policy, mainly in relation to the quarantine guidelines.Finally, although the pathogenesis of COVID-19 is complex and multifactorial, properly addressing the above issues is essential for understanding the pathogenic mechanisms of SARS-CoV-2. We believe that knowledge accumulated on SARS-CoV and MERS-CoV, in addition to studies with animal coronaviruses, is fundamental to direct future investigations, as well as an additional and useful tool for the management of future pandemics.Author Disclosure StatementNo competing financial interests exist.Funding InformationNo funding was received for this study.References1. Baric RS, Sheahan T, Deming D, et al. SARS coronavirus vaccine development. Adv Exp Med Biol 2006;581:553–560. Crossref, Medline, Google Scholar2. Casadevall A, and Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest 2020;130:1545–1548. Crossref, Medline, Google Scholar3. Centers for Disease Control and Prevention. CDC SARS response timeline, 2013. https://www.cdc.gov/about/history/sars/timeline.htm (accessed March 18, 2020). Google Scholar4. Centers for Disease Control and Prevention. Severe Acute Respiratory Syndrome (SARS), 2017. https://www.cdc.gov/sars/about/fs-sars.html (accessed March 18, 2020). Google Scholar5. Centers for Disease Control and Prevention. Pathophysiology of severe dengue, 2019. https://www.cdc.gov/dengue/training/cme/ccm/Severe%20Disease%20in%20Infants_F.pdf (accessed March 18, 2020). Google Scholar6. Centers for Disease Control and Prevention. Coronavirus, 2020. https://www.cdc.gov/coronavirus/types.html (accessed March 18, 2020). Google Scholar7. Corapi WV, Olsen CW, and Scott FW. Monoclonal antibody analysis of neutralization and antibody-dependent enhancement of feline infectious peritonitis virus. J Virol 1992;66:6695–6705. Crossref, Medline, Google Scholar8. Cui J, Li F, and Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181–192. Crossref, Medline, Google Scholar9. Fang L, Karakiulakis G, and Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21. Crossref, Medline, Google Scholar10. Gan ES, Ting DH, and Chan KR. The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis. Expert Rev Anti Infect Ther 2017;15:111–119. Crossref, Medline, Google Scholar11. Hua CK, and Ackerman ME. Increasing the clinical potential and applications of anti-HIV antibodies. Front Immunol 2017;8:1655. Crossref, Medline, Google Scholar12. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506. Crossref, Medline, Google Scholar13. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:1–10. Crossref, Medline, Google Scholar14. Hohdatsu T, Yamada M, Tominaga R, et al. Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. J Vet Med Sci 1998;60:49–55. Crossref, Medline, Google Scholar15. International Committee on Taxonomy of Viruses. Virus taxonomy: 2018 release, 2018. https://talk.ictvonline.org/taxonomy (accessed March 18, 2020). Google Scholar16. Jaume M, Yip MS, Cheung CY, et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcR pathway. J Virol 2011;85:10582–10597. Crossref, Medline, Google Scholar17. Kam YW, Kien F, Roberts A, et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcRII-dependent entry into B cells in vitro. Vaccine 2007;25:729–740. Crossref, Medline, Google Scholar18. Kuzmina NA, Younan P, Gilchuk P, et al. Antibody-dependent enhancement of ebola virus infection by human antibodies isolated from survivors. Cell Rep 2018;24:1802–1815. Crossref, Medline, Google Scholar19. Masters PS, and Perlman S. Coronaviridae. In: Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins, 2013:825–858. Google Scholar20. Naqi S, Gay K, Patalla P, et al. Establishment of persistent avian infectious bronchitis virus infection in antibody-free and antibody-positive chickens. Avian Dis 2003;47:594–601. Crossref, Medline, Google Scholar21. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 2020;41:145–151. Medline, Google Scholar22. Raj GD, and Jones RC. Infectious bronchitis virus: immunopathogenesis of infection in the chicken. Avian Pathol 1997;26:677–706. Crossref, Medline, Google Scholar23. Tetro JA. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect 2020;22:72–73. Crossref, Medline, Google Scholar24. Vennema H, de Groot RJ, Harbour DA, et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J Virol 1990;64:1407–1409. Crossref, Medline, Google Scholar25. Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94:e00127-20. Crossref, Medline, Google Scholar26. Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020;94:e02015–e02019. Crossref, Medline, Google Scholar27. Wang SF, Tseng SP, Yen CH, et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun 2014;451:208–214. Crossref, Medline, Google Scholar28. Winarski KL, Tang J, Klenow L, et al. Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics. Proc Natl Acad Sci USA 2019;116:15194–15199. Crossref, Medline, Google Scholar29. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV), 2020. https://www.who.int/emergencies/mers-cov/en (accessed March 18, 2020). Google Scholar30. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020, 2020. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19–11-march-2020 (accessed March 18, 2020). Google Scholar31. Zhao J, Alshukairi AN, Baharoon SA, et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol 2017;2:eaan5393. Crossref, Medline, Google Scholar32. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–733. Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited byEpidemiological analysis over two years of SARS-CoV-2 circulation in southern Brazil: old and novel predictors of COVID-19 outcomeActa Tropica, Vol. 247Structural and Functional Insights of Thiazole Derivatives as Potential Anti-inflammatory Candidate: A New Contender on Chronic and Acute SARS-CoV-2 Inflammation and Inhibition of SARS-CoV-2 Proteins18 July 2022 | Asian Journal of Chemistry, Vol. 34, No. 8Case Report: COVID-19 with cytokine storm in a 16-year-old patient: if heart failures comes think about levosimendan26 March 2021 | F1000Research, Vol. 10Case Report: COVID-19 with cytokine storm in a 16-year-old patient: if heart failures comes think about levosimendan7 February 2023 | F1000Research, Vol. 10 Volume 34Issue 5Jun 2021 InformationCopyright 2021, Mary Ann Liebert, Inc., publishersTo cite this article:José Valter Joaquim Silva Júnior, Thaísa Regina Rocha Lopes, Pablo Sebastian Britto de Oliveira, Rudi Weiblen, and Eduardo Furtado Flores.Letter to the Editor: Issues on COVID-19 Pathogenesis.Viral Immunology.Jun 2021.358-360.http://doi.org/10.1089/vim.2020.0059Published in Volume: 34 Issue 5: June 14, 2021Online Ahead of Print:April 27, 2020 TopicsCOVID-19 PDF download